Component

Insulin-suppressed hepatic glucose output after four weeks of vanadyl

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In eight patients given 50 mg vanadyl sulfate twice daily for four weeks, fasting glucose and hepatic glucose output during insulin infusion decreased, without significant whole-body glucose-uptake improvement.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Single-blind sequential study; six patients continued to a subsequent placebo phase.
    limitations
    Fixed treatment order and persistence into placebo complicate causal inference; six of eight had early gastrointestinal effects.
    nutrient_topic
    Vanadium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Vanadium
    plain_language
    Another small study found a liver-associated effect rather than broad uptake improvement.
    primary_references
    Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. · 1996 · https://pubmed.ncbi.nlm.nih.gov/8781301/ · DOI 10.1016/s0026-0495(96)90013-x

    Vanadium: speciation, phosphate-sensitive enzymes and cross-nutrient mechanisms (2026-09-19) · lines 438–444

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Single-blind sequential study; six patients continued to a subsequent placebo phase. · source_derived_draft · unverified_draft

    ## vanadium-human-small-hepatic-positive Another small study found a liver-associated effect rather than broad uptake improvement. In eight patients given 50 mg vanadyl sulfate twice daily for four weeks, fasting glucose and hepatic glucose output during insulin infusion decreased, without significant whole-body glucose-uptake improvement. Model: Single-blind sequential study; six patients continued to a subsequent placebo phase. Limitations: Fixed treatment order and persistence into placebo complicate causal inference; six of eight had early gastrointestinal effects. Evidence access: Primary abstract Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. · 1996 · https://pubmed.ncbi.nlm.nih.gov/8781301/ · DOI 10.1016/s0026-0495(96)90013-x
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards